Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

608

Shown on this page

Current sort

Live official records

Conditions: Bladder Cancer
Interventions: Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system; Drug · Device
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Enrollment: 4,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions: Mavyret; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Interventions: Daromun, Surgery, Adjuvant therapy; Drug · Procedure
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 19
States / cities: Phoenix, Arizona • La Jolla, California • Orange, California + 16 more

Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 446
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more

Conditions: Unresectable Metastatic Colorectal Cancer
Interventions: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more

Conditions: Crohns Disease
Interventions: TRX103, Cyclophosphamide; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Interventions: MK-4002; Drug
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more

Conditions: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Interventions: Eplontersen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 8
States / cities: Scottsdale, Arizona • Indianapolis, Indiana • Baltimore, Maryland + 5 more

Conditions: Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: HFB200301, Tislelizumab; Drug
Lead sponsor: HiFiBiO Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more

Conditions: COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2,981 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Sarcoma, Giant Cell Tumor of Bone
Interventions: Surgery; Procedure
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Phoenix, Arizona • Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Focus group analyses; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 95 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

Blue Light Cystoscopy With Cysview® Registry

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Treatment of Moderate to Severe Refractory Crohn's Disease

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Study of COPD Subgroups and Biomarkers

PROMIS and Mobility Evaluation in Sarcoma Patients

Understanding of Genetics by Men at Risk for Prostate Cancer

About this Mayo Clinic institution page